As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to:www.eastmoney.com
Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global:
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China:
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
NAFL:
It is completely reversible and can be reversed through diet control, exercise and other healthy lifestyles. Drug therapy mainly aims to improve lipid metabolism.
NASH:
It is a progressive form of nonalcoholic fatty liver disease, characterized by a metabolically stressful liver injury closely associated with insulin resistance and genetic predisposition. NASH can advance to cirrhosis and hepatocellular carcinoma and is also significantly associated with an increased risk of cardiovascular disease.
The etiology of NASH is complex, and its exact pathogenesis is unknown. Currently, there is no specific treatment or drug therapy for NASH.
Therapeutic drugs targeting different targets in NASH have become one of the current hotspots in research and development, focusing on various pathogenic mechanisms of NASH such as liver metabolism, inflammation, oxidative stress, fibrosis, etc.